Thyroid hormone replacement: current status and challenges
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Correction of hypothyroidism with synthetic levothyroxine is simple, effective and safe. In most cases levothyroxine restores well-being and normalizes serum thyrotropin (TSH) concentrations. However, up to 30 - 50% of levothyroxine users do not achieve adequate biochemical euthyroidism. Also, a small proportion of hypothyroid individuals remain dissatisfied with treatment even with normal TSH concentrations. AREAS COVERED: This review addresses strategies for achieving optimal thyroid hormone replacement based on a systematic search of the literature for controlled trials, cohort studies or systematic reviews published on the topic since 1960. EXPERT OPINION: Careful attention to factors that affect levothyroxine availability such as medication adherence, drug interactions and co-morbidities should improve the adequacy of therapy, but these factors are challenging to manage in practice. The case for combined therapy with levothyroxine and triiodothyronine (T3) is compelling but is not supported by current evidence from randomized controlled trials. Recent studies of common genetic variations in deiodinase and thyroid hormone transport proteins offer fresh insights in understanding the variable response to thyroid hormone therapy and future research may clarify whether subsets of patients will benefit from combined therapy. Despite significant challenges, opportunities abound for improving therapeutic outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Haddow, J. E., Palomaki, G. E., Allan, W. C., Williams, J. R., Knight, G. J., Gagnon, J., O'Heir, C. E., Mitchell, M. L., Hermos, R. J., Waisbren, S. E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410801 · Cited by 2,558
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418 · cited 6×
“function indistinguishable from that seen in overt hypothyroidism [6].”
BackgroundInfluentialLow Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259 · cited 1×
“Thyroid hormone excess increases the risks of atrial fibrillation [13,50-51], osteoporosis [13,52-53] and fractures [54].”
BackgroundLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Subclinical hypothyroidism and pregnancy outcomes
Casey, B. M., Dashe, J. S., Wells, C. E., McIntire, D. D., Byrd, W., Leveno, K. J., & Cunningham, F. G. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000152345.99421.22 · Cited by 903
Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults
Cappola, A. R., Fried, L. P., Arnold, A. M., Danese, M. D., Kuller, L. H., Burke, G. L., Tracy, R. P., & Ladenson, P. W. (2006) · JAMA · doi:10.1001/jama.295.9.1033 · Cited by 862 · cited 1×
“Thyroid hormone excess increases the risks of atrial fibrillation [13,50-51], osteoporosis [13,52-53] and fractures [54].”
BackgroundDuntas, L. H. (2002) · Thyroid · doi:10.1089/10507250252949405 · Cited by 725
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686 · cited 1×
“However, the intra-individual range is maintained within comparatively narrower limits [107].”
BackgroundRoberts, C. G., & Ladenson, P. W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15696-1 · Cited by 567
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 5×
“0 0 1:10, 1:5 Yes No (QOL, M, PP) Levitt, 2005 [83] 50 100.”
BackgroundMethodInfluentialRisk for fracture in women with low serum levels of thyroid-stimulating hormone
Bauer, D. C., Ettinger, B., Nevitt, M. C., Stone, K. L., & for the Study of Osteoporotic Fractures Research Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00009 · Cited by 467
Flynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
Thyroid hormone replacement for subclinical hypothyroidism
Villar, H. C. C. E., Saconato, H., Valente, O., & Atallah, Á. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003419.pub2 · Cited by 329
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 2×
“These increased dose requirements were reversed with treatment [71].”
BackgroundPanicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Levothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 1×
“Another study in euthyroid patients on levothyroxine therapy showed no relationship between TSH concentration and cognitive function or psychological well-being [44].”
BackgroundGrozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296 · cited 1×
“A more recent meta-analysis, which included 11 controlled studies comprising 1216 patients, found no advantage of combined therapy over sole T4 therapy in quality of life and well-being [96].”
MethodEscobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286 · cited 5×
“Studies have shown improved outcomes with TSH suppression in DTC patients [34-36].”
BackgroundInfluentialAge- and Race-Based Serum Thyrotropin Reference Limits
Surks, M. I., & Boucai, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1845 · Cited by 258 · cited 1×
“TSH levels increase with advancing age, a shift which by itself is not indicative of thyroid dysfunction [108].”
BackgroundSomwaru, L. L., Arnold, A. M., Joshi, N., Fried, L. P., & Cappola, A. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1696 · Cited by 239 · cited 5×
“1 Prevalence of inadequate thyroid hormone replacement Despite the simplicity of thyroid hormone replacement, crosssectional studies in general populations show that inadequate replacement is prevalent (Table 1) [2,3,9-15].”
BackgroundResultInfluentialLean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases
Santini, F., Pinchera, A., Marsili, A., Ceccarini, G., Castagna, M. G., Valeriano, R., Giannetti, M., Taddei, D., Centoni, R., Scartabelli, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1306 · Cited by 226 · cited 1×
“Although levothyroxine dose is routinely based on total body weight, lean body mass is a more accurate determinant of levothyroxine requirements [60].”
BackgroundConditions and drugs interfering with thyroxine absorption
Liwanpo, L., & Hershman, J. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.006 · Cited by 222 · cited 1×
“A number of dietary substances, drugs and comorbid conditions impair its absorption (Box 2) [38,39].”
BackgroundTriiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216 · cited 1×
“In fact, normal serum T3 concentrations are seen in thyroidectomized individuals on T4 monotherapy, indicating efficient peripheral synthesis of T3 in man [79].”
BackgroundWalsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Accelerated Bone Loss in Hypothyroid Patients Overtreated with L-Thyroxine
Stall, G. M., Harris, S., Sokoll, L. J., & Dawson-Hughes, B. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-4-265 · Cited by 203
Timing of levothyroxine administration affects serum thyrotropin concentration
Bach-Huynh, T.-G., Nayak, B., Loh, J., Soldin, S., & Jonklaas, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0860 · Cited by 198 · cited 2×
“By contrast, a randomized, controlled crossover study in 65 patients showed that ingesting levothyroxine 1 h before breakfast led to a better TSH response than bedtime administration [62].”
BackgroundResultClyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195 · cited 4×
“Briefly, some protocols used fixed T3 doses in combination with varying amounts of T4 resulting in a range of T3:T4 ratios that do not mimic the human thyroid secretion ratio of 1:14 (Table 2) [83-85,88-90,93-95].”
BackgroundMethodInfluentialAppelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182 · cited 4×
“The vast majority of trials have focused on patients with primary autoimmune thyroiditis (Table 2) [85,87-94].”
BackgroundInfluentialManagement of hypothyroidism in adults
Vaidya, B., & Pearce, S. H. S. (2008) · BMJ · doi:10.1136/bmj.a801 · Cited by 178
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175 · cited 4×
“Briefly, some protocols used fixed T3 doses in combination with varying amounts of T4 resulting in a range of T3:T4 ratios that do not mimic the human thyroid secretion ratio of 1:14 (Table 2) [83-85,88-90,93-95].”
BackgroundMethodInfluentialWalsh, J. P., Ward, L. C., Burke, V., Bhagat, C. I., Shiels, L., Henley, D., Gillett, M. J., Gilbert, R., Tanner, M., & Stuckey, B. G. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0099 · Cited by 164
Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160 · cited 4×
“For example, humans have higher concentrations of thyroidbinding globulins and exhibit a greater capacity for buffering and release of thyroid hormones than rats (reviewed in [78]).”
BackgroundInfluentialNygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Levothyroxine dose and risk of fractures in older adults: nested case-control study
Turner, M. R., Camacho, X., Fischer, H. D., Austin, P. C., Anderson, G. M., Rochon, P. A., & Lipscombe, L. L. (2011) · BMJ · doi:10.1136/bmj.d2238 · Cited by 152 · cited 1×
“Recent reports showing an association between fracture risk and levothyroxine treatment in the elderly attest to this [55].”
BackgroundSiegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152 · cited 2×
“Since then, at least a dozen more randomized, controlled trials have attempted to replicate these initial findings [84-94].”
BackgroundRoos, A., Linn-Rasker, S. P., van Domburg, R. T., Tijssen, J. P., & Berghout, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1714 · Cited by 150 · cited 1×
“A randomized, controlled trial in patients with primary hypothyroidism showed that a full starting dose was safe, convenient and cost-effective [40].”
BackgroundSaravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1672 · Cited by 136 · cited 4×
“Briefly, some protocols used fixed T3 doses in combination with varying amounts of T4 resulting in a range of T3:T4 ratios that do not mimic the human thyroid secretion ratio of 1:14 (Table 2) [83-85,88-90,93-95].”
BackgroundMethodInfluentialEffects of Evening vs Morning Levothyroxine Intake: A Randomized Double-blind Crossover Trial
Bolk, N. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.436 · Cited by 128 · cited 1×
“A randomized, control trial in patients with primary hypothyroidism showed that bedtime thyroxine administration was associated with a better biochemical response than morning administration [61].”
BackgroundIncreased central arterial stiffness in hypothyroidism
Obuobie, K., Smith, J., Evans, L. M., John, R., Davies, J. S., & Lazarus, J. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020493 · Cited by 119
Novel insights into thyroid hormones from the study of common genetic variation
Dayan, C. M., & Panicker, V. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.19 · Cited by 110 · cited 2×
“The possibility of a molecular basis for the variable individual response to thyroid hormone replacement therapy has attracted recent interest [101].”
BackgroundSmith, R. N., Taylor, S. A., & Massey, J. C. (1970) · BMJ · doi:10.1136/bmj.4.5728.145 · Cited by 106 · cited 3×
“0 0 Variable NA No (QOL, M, PP) Appelhof, 2005 [82] 141 100.”
BackgroundThyroid Disease and Vascular Function
Owen, P. J. D., Sabit, R., & Lazarus, J. H. (2007) · Thyroid · doi:10.1089/thy.2007.0051 · Cited by 101 · cited 1×
“The vascular effects of hypothyroidism include raised systemic vascular resistance, diastolic hypertension, increased central arterial stiffness and endothelial dysfunction, all of which amplify cardiovascular disease risk [56-58].”
BackgroundVan Der Deure, W. M., Appelhof, B. C., Peeters, R. P., Wiersinga, W. M., Wekking, E. M., Huyser, J., Schene, A. H., Tijssen, J. G. P., Hoogendijk, W. J. G., Visser, T. J., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03267.x · Cited by 97
Adequacy of thyroid hormone replacement in a general population
Okosieme, O. E., Belludi, G., Spittle, K., Kadiyala, R., & Richards, J. (2011) · QJM · doi:10.1093/qjmed/hcq222 · Cited by 96 · cited 5×
“15 mU/liter) Okosieme, 2011 [15] 1037 62 86 General practice 20 17 ECLA (0.”
BackgroundResultInfluentialSelf-citationTorlontano, M., Durante, C., Torrente, I., Crocetti, U., Augello, G., Ronga, G., Montesano, T., Travascio, L., Verrienti, A., Bruno, R., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1067 · Cited by 92
Diez, J. J. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m315 · Cited by 91 · cited 4×
“…[2] 1525 NS NS Community survey 22 18 ICLA (0.3 -- 5.1 mU/liter) Hollowell, 2000 [3] 820* NS 84 Community survey 18 15 CLIA (0.39 -- 4.6 mU/liter) Diez, 2002 [11] 385 65 87 Hospital clinic 5 28 IEA (0.4 -- 5.0 mU/liter) Somwaru, 2009 [12] 339 73 NS Community surveyz 41 16 CLIA (0.45 -- 4.49…”
BackgroundInfluentialHennemann, G., Docter, R., Visser, T. J., Postema, P. T., & Krenning, E. P. (2004) · Thyroid · doi:10.1089/105072504323030924 · Cited by 90
Saravanan, P., Visser, T. J., & Dayan, C. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0414 · Cited by 90
l-Thyroxine Requirement in Patients with Autoimmune Hypothyroidism and Parietal Cell Antibodies
Checchi, S., Montanaro, A., Pasqui, L., Ciuoli, C., De Palo, V., Chiappetta, M. C., & Pacini, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1544 · Cited by 89 · cited 3×
“Interestingly, thyroxine requirements correlated with serum concentrations of parietal cell antibodies [72].”
BackgroundInfluentialLania, A., Persani, L., & Beck-Peccoz, P. (2008) · Pituitary · doi:10.1007/s11102-008-0122-6 · Cited by 85 · cited 1×
“The therapeutic target in these cases should therefore be to keep serum FT4 levels within the reference range [48].”
BackgroundRodriguez, T., Lavis, V. R., Meininger, J. C., Kapadia, A. S., & Stafford, L. F. (2005) · Endocrine Practice · doi:10.4158/ep.11.4.223 · Cited by 80
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Illouz, F., Laboureau-Soares, S., Dubois, S., Rohmer, V., & Rodien, P. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0648 · Cited by 77 · cited 3×
“A number of recent reports have highlighted the association of thyroid dysfunction with the new tyrosine kinase inhibitors such as sunitinib and imatinib, which are now increasingly used in the treatment of solid and haematological malignancies [74].”
BackgroundInfluentialJoffe, R. T., Brimacombe, M., Levitt, A. J., & Stagnaro-Green, A. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.5.379 · Cited by 57 · cited 2×
“Briefly, some protocols used fixed T3 doses in combination with varying amounts of T4 resulting in a range of T3:T4 ratios that do not mimic the human thyroid secretion ratio of 1:14 (Table 2) [83-85,88-90,93-95].”
MethodResultWard, L. S. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000500002 · Cited by 53 · cited 1×
“4 Co-morbid conditions Thyroxine availability is reduced by a variety of conditions that either interfere with its absorption or increase its clearance (Box 2) [38,68].”
BackgroundHeemstra, K. A., Hoftijzer, H. C., Van Der Deure, W. M., Peeters, R. P., Fliers, E., Appelhof, B. C., Wiersinga, W. M., Corssmit, E. P. M., Visser, T. J., & Smit, J. W. A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03474.x · Cited by 51
TSH-Based Protocol, Tablet Instability, and Absorption Effects on L-T 4 Bioequivalence
Eisenberg, M., & Distefano, J. J. (2009) · Thyroid · doi:10.1089/thy.2008.0148 · Cited by 43 · cited 2×
“Minor differences in tablet potency between equivalent products and loss of potency over the course of the tablet shelf-life may have clinically significant effects [75].”
BackgroundTwice-weekly dosing for thyroxine replacement in elderly patients with primary hypothyroidism
Taylor, J., Williams, B. O., Frater, J., Stott, D. J., & Connell, J. (1994) · Journal of International Medical Research · doi:10.1177/030006059402200504 · Cited by 30
Thyroxine adherence in primary hypothyroidism
Crilly, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16172-2 · Cited by 16 · cited 1×
“with primary hypothyroidism admitted to levothyroxine noncompliance [65].”
Background
Cited by
Thyroxine replacement: a clinical endocrinologist’s viewpoint
Eligar, V, Taylor, P., Okosieme, O., Leese, G., & Dayan, C. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216642255 · Cited by 72
Self-citationDew, R., King, K., Okosieme, O. E., Pearce, S. H., Donovan, G., Taylor, P. N., Hickey, J., Dayan, C. M., Leese, G., Razvi, S., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019970 · Cited by 31
Self-citationDucharme, M., Scarsi, C., Bettazzi, E., Mautone, G., Lewis, Y., & Celi, F. S. (2022) · Thyroid · doi:10.1089/thy.2021.0604 · Cited by 13
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf449 · Cited by 11
“Early therapy for hypothyroidism relied on desiccated thyroid extracts (DTE), which was eventually replaced by synthetic preparations in the 1960s (5).”
Self-citation
Metadata
- Authors
- Okosieme, O. E.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-07-16
- Volume
- 12
- Issue
- 15
- Pages
- 2315-2328
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2101527194
- Cited by
- 35
- References
- 63
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.